Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pervasive chromosomal instability and karyotype order in tumour evolution.
Watkins TBK, Lim EL, Petkovic M, Elizalde S, Birkbak NJ, Wilson GA, Moore DA, Grönroos E, Rowan A, Dewhurst SM, Demeulemeester J, Dentro SC, Horswell S, Au L, Haase K, Escudero M, Rosenthal R, Bakir MA, Xu H, Litchfield K, Lu WT, Mourikis TP, Dietzen M, Spain L, Cresswell GD, Biswas D, Lamy P, Nordentoft I, Harbst K, Castro-Giner F, Yates LR, Caramia F, Jaulin F, Vicier C, Tomlinson IPM, Brastianos PK, Cho RJ, Bastian BC, Dyrskjøt L, Jönsson GB, Savas P, Loi S, Campbell PJ, Andre F, Luscombe NM, Steeghs N, Tjan-Heijnen VCG, Szallasi Z, Turajlic S, Jamal-Hanjani M, Van Loo P, Bakhoum SF, Schwarz RF, McGranahan N, Swanton C. Watkins TBK, et al. Among authors: vicier c. Nature. 2020 Nov;587(7832):126-132. doi: 10.1038/s41586-020-2698-6. Epub 2020 Sep 2. Nature. 2020. PMID: 32879494 Free PMC article.
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants.
Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L. Messaoudene M, et al. Among authors: vicier c. Ann Oncol. 2019 Jun 1;30(6):934-944. doi: 10.1093/annonc/mdz112. Ann Oncol. 2019. PMID: 30924846 Free PMC article.
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
Patsouris A, Diop K, Tredan O, Nenciu D, Gonçalves A, Arnedos M, Sablin MP, Jézéquel P, Jimenez M, Droin N, Bièche I, Callens C, Loehr A, Vicier C, Guerin C, Filleron T, André F. Patsouris A, et al. Among authors: vicier c. Eur J Cancer. 2021 Dec;159:283-295. doi: 10.1016/j.ejca.2021.09.028. Epub 2021 Nov 25. Eur J Cancer. 2021. PMID: 34837859 Free article. Clinical Trial.
Clinical development of mTOR inhibitors in breast cancer.
Vicier C, Dieci MV, Arnedos M, Delaloge S, Viens P, Andre F. Vicier C, et al. Breast Cancer Res. 2014 Feb 17;16(1):203. doi: 10.1186/bcr3618. Breast Cancer Res. 2014. PMID: 25189767 Free PMC article. Review.
Chk1 as a new therapeutic target in triple-negative breast cancer.
Albiges L, Goubar A, Scott V, Vicier C, Lefèbvre C, Alsafadi S, Commo F, Saghatchian M, Lazar V, Dessen P, Delaloge S, André F, Quidville V. Albiges L, et al. Among authors: vicier c. Breast. 2014 Jun;23(3):250-8. doi: 10.1016/j.breast.2014.02.004. Epub 2014 Mar 15. Breast. 2014. PMID: 24636978
40 results